Berkshire Hathaway Inc. (Class B) (BRK-B)
Verdict history · BRK-B
Every call Verdix has made on BRK-B.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
When the prior article ran at $504, the panel saw value but hesitated because management had not yet signaled conviction through buybacks and two voices leaned bearish on entry timing. Since then, the $4.5B Q2 buyback — the largest quarterly repurchase in over three years — changed the signal: management is now actively buying below intrinsic value. The price easing to $496 only widens the modest discount, and with The GARP Operator replacing two formerly cautious voices, the arithmetic tips from WAIT to BUY.
See methodology for how verdicts are produced. Full track record →
The panel’s case for BRK-B — and where they disagree.
The case for outweighs the case against at today's price.
NYSE · Financials / Diversified Holding Company · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BuyMEDIUM confidence
Why
Five distinct analytical frameworks examine Berkshire Hathaway after management's $4.5B quarterly buyback — the largest in over three years — and four conclude the stock is a BUY at $495.82, with the lone neutral voice holding out for a wider discount rather than questioning the business. The effective price of the operating businesses, after backing out $167.71 per share in net cash, sits at roughly $328, and the debate turns on whether management can productively deploy the remaining $365B cash hoard.Level to watch
Key support 492.17−0.7% from 495.82
Next catalyst
Trigger to confirm the breakout: A weekly close above $500.88 with expanding volume would confirm the uptrend is reasserting itself and would lift conviction across the panel.The panel's take
Verdict: BUY · Conviction: MEDIUM · Last price: 495.82 · Changed from WAIT
Panel: 4 Bullish · 1 Neutral · 0 Bearish → BUY
What changed since 2026-08-15:
- Price: 504.03 → 495.82 (-1.63%)
- Panel: 4 of 6 → 4 of 5 now Bullish — composition also changed: added The GARP Operator; removed The Asymmetric Bargainer, The Margin-of-Safety Hunter
- Trigger: A weekly close below $483.27 — the volume POC that marks the highest-conviction accumulation zone on both the monthly and weekly timeframes. A break below it would signal distribution is underway, and multiple voices (The Moat Compounder, The Forensic Skeptic, the technical scout) name it as the level that would negate the bullish case.
- Verdict: WAIT → BUY
When the prior article ran at $504, the panel saw value but hesitated because management had not yet signaled conviction through buybacks and two voices leaned bearish on entry timing. Since then, the $4.5B Q2 buyback — the largest quarterly repurchase in over three years — changed the signal: management is now actively buying below intrinsic value. The price easing to $496 only widens the modest discount, and with The GARP Operator replacing two formerly cautious voices, the arithmetic tips from WAIT to BUY.
Four of five voices see Berkshire as a BUY. The common thread is that management's $4.5B Q2 buyback — the largest in over three years — is the loudest possible signal of undervaluation, the $167/share in net cash provides an enormous margin of safety, and the operating businesses, effectively priced at ~$328/share, are high-quality compounders at a reasonable multiple. The lone neutral, The Forensic Skeptic, agrees the business is wonderful and modestly undervalued but holds out for a wider discount; his objection is on price, not quality. With four voices affirming the durable moat, fortress balance sheet, and management conviction, BUY is the arithmetic reading.
Key levels
Key levels · BRK-B
USD · as of 2026-08-22Analyst consensus target 486.91 USD · range 482–606
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key support at $490.80 is the weekly EMA50 — the structural floor of the Stage 2 uptrend; a close below it breaks the bullish EMA stack. The volume POC at $483.27 is the highest-volume price node on both monthly and weekly timeframes, a historical accumulation zone where buyers have consistently absorbed supply. Key resistance begins at $500.88, the 50% Fibonacci retracement of the $464–$538 range that the technical scout identifies as the level that would reassert Stage 2 momentum on a weekly close. The all-time high at $542.07 is the ultimate ceiling and a historical resistance zone. The stale analyst consensus target of $486.91 (April 2025) sits just below current price; Morningstar's more recent fair value estimate of $510 lands inside the Fibonacci resistance band between $500.88 and $516.85.
What legendary investors think
We ran Berkshire Hathaway Inc. (Class B) past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The Moat CompounderValue/Quality/Moat🟢 BullishMed
Signal: With $167.71 per share in net cash on the balance sheet, the operating businesses are effectively priced at ~$328 per share, and management's $4.5B Q2 buyback confirms they see that as a bargain. Conviction: Conviction is reinforced by multiple independent signals: the $4.5B buyback, insider purchases, and a 0.17x debt-to-equity ratio that leaves almost no financial risk on the table.
The Intrinsic-Value ModelerValuation/DCF🟢 BullishMed
Signal: A sum-of-the-parts framework assigns $540 to $570 per share to the collection of operating businesses, equity portfolio, and excess cash, yielding 9-15% upside from the current $495.82. Conviction: Conviction holds at medium because the upside, while real, depends heavily on management deploying the $365B cash pile productively rather than letting it sit as a drag on returns.
The Quality RationalistMental Models/Quality🟢 BullishMed
Signal: The $4.5B Q2 buyback at 1.45x book value is a clear vote of owner-confidence, and the company's collection of durable low-cost positions in insurance and rail cannot be replicated by any competitor. Conviction: The one thing that tempers conviction is the $365B cash hoard, which drags down aggregate ROE to 12% and will only stop being a weight if management accelerates deployment.
The Forensic SkepticContrarian/Forensic⚫ NeutralMed
Signal: Normalized operating earnings of roughly $21 per share, when stripped of non-cash investment gains, put the effective P/E on the operating business near 15x, and the market assigns zero value to Berkshire's ability to redeploy its $365B cash pile. Conviction: The hesitation comes from a margin of safety that sits at just 8-17%, which is narrower than a deep-value framework demands, even for a business of this quality.
The GARP OperatorGrowth (GARP)🟢 BullishLow
Signal: Trailing P/E of ~12.5x against an estimated growth rate of ~12% yields a PEG ratio near 1.0, and the $167.71 in net cash per share means the operating business alone sells for roughly 8-9x operating earnings. Conviction: Confidence sits at the lower end because the projected growth rate is not confirmed by a current consensus estimate, making the PEG calculation provisional rather than settled.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All five voices recognize management's $4.5B Q2 buyback as a meaningful signal of undervaluation.
- All agree the $167.71 per share net cash position provides substantial downside protection regardless of framework.
- The operating businesses (GEICO, BNSF, utilities, manufacturing) are viewed as high-quality and durable across every archetype.
- None of the five sees material accounting red flags or balance sheet risk in the Berkshire structure.
The real debate
- The Forensic Skeptic sees the 8-17% margin of safety as insufficient for a deep-value commitment, while The Moat Compounder and The Quality Rationalist argue that management's own buyback at these levels effectively validates the price as below intrinsic value.
- The GARP Operator needs a confirmed growth rate to anchor the PEG framework, while The Intrinsic-Value Modeler is comfortable with a sum-of-the-parts approach that does not require a growth forecast at all.
The question it comes down to: Can Berkshire deploy its $365B cash pile at attractive rates of return before the opportunity cost of holding cash erodes the margin of safety embedded in the current price?
The bottom line
- Trigger to confirm the breakout: A weekly close above $500.88 with expanding volume would confirm the uptrend is reasserting itself and would lift conviction across the panel.
- Risk to the bullish case: A weekly close below $483.27, the volume point of control that marks the highest-conviction accumulation zone, would signal distribution is underway and negate the undervaluation thesis.
- Next catalyst: The Q3 2026 buyback figure: if it matches or exceeds the $4.5B Q2 pace, the market will likely re-rate the stock as management doubles down on its own undervaluation signal.
- Further out: A large, sensible acquisition that deploys a meaningful portion of the $365B cash pile at high returns would push fair value estimates toward $600 or higher across multiple valuation frameworks.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in BRK-B · BRK-B verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated